Cognitive Impairment and Upper Extremity Performance in COPD

Izmir Katip Celebi University

Status: Unknown

Conditions: Cognitive Impairment; Upper Limb Function; Upper Extremity; COPD

Treatments: Other: Functional tests

Study type: Observational

Funder types: Other

Identifiers

NCT05137483

IKC125

Details and patient eligibility

About

Within the scope of this study, COPD patients will be divided into two groups according to cognitive dysfunction.

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.

Full description

Although the mechanism of cognitive dysfunction in COPD is not clear, the reasons focused on are; decreased oxygen use, high carbon dioxide levels, increased inflammation and oxidative stress, decreased physical activity, peripheral vascular diseases, atherosclerosis, high or low blood pressure, cerebral vasoconstriction, increased intracranial pressure, accompanying comorbidities, smoking and genetic predisposition, brain damage and exacerbations have been reported. Few studies have shown that cognitive dysfunction is associated with functional performance. There are no studies on the effect of cognitive function on upper extremity performance and mechanisms of action in COPD patients.

The aim of this study is to compare upper extremity functional capacities, respiratory functions, fatigue and quality of life in COPD patients with and without cognitive function impairment.

Within the scope of this study, COPD patients will be divided into two groups according to cognitive dysfunction.

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.

Enrollment: 80 estimated patients

Sex: All

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Volunteering to participate in the study
• Stage 2-3-4 according to the GOLD classification in the 40-65 age range

Exclusion criteria

• Exacerbation of respiratory symptoms in the past 4 weeks (change in breathlessness and/or sputum volume/color, need for antibiotic treatment or need for hospitalization)
• Presence of asthma, unstable coronary heart disease, uncontrolled diabetes, hypertension, left-sided congestive heart failure, neoplasia, severe claudication, encephalitis or epilepsy
• Having a history of head trauma or brain tumor
• Having a significant psychiatric condition or the presence of defined dementia, according to the American Psychiatric Association

Trial design

80 participants in 2 patient groups

With cognitive impairment

Description:

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.

Treatment:

Other: Functional tests

without cognitive impairment

Description:

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.

Treatment:

Other: Functional tests